Sponsor or institution
Clinical trials and research at Hebei Medical University Fourth Hospital
As of November 12, 2026, Find a Trial lists 29 clinical trials run by Hebei Medical University Fourth Hospital that are recruiting, in China. By phase: Phase 2 (19), Phase 1 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 29Clinical trials
- 1Country
Newest trials
All recruiting trials (29)
-
SABR with Axitinib and Toripalimab for oligometastatic kidney cancer
This phase 2 trial tests whether giving SABR radiation together with axitinib and toripalimab can shrink tumors and help patients with up to five metastatic sites from clear cell renal cell carcinoma.
-
Cardiac Safety After Thoracic Radiotherapy in Adults
We’re testing how well cardiac safety checks after thoracic radiotherapy can spot early heart changes in adults with chest tumors.
-
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.
-
Dalpiciclib with or without entinostat plus letrozole for HR-positive, HER2-negative early breast cancer
This tests whether adding the CDK4/6 drug dalpiciclib, with or without the HDAC blocker entinostat, to the hormone pill letrozole helps shrink tumors in people with HR+/HER2- early breast cancer.
-
Trilaciclib plus chemotherapy for CDK4/6-dependent solid tumors
This trial will try adding trilaciclib to chemotherapy to protect the bone marrow of people with CDK4/6-dependent solid tumors from severe drops in blood counts.
-
Short-course Radiotherapy Plus Enlonstobart in pMMR Locally Advanced Rectal Cancer
This study tests a short course of radiotherapy combined with enlonstobart in adults with pMMR locally advanced rectal cancer to see if this approach is safe and effective.
-
Preventing neutropenia after cancer treatment with mecapegfilgrastim injections
This will try mecapegfilgrastim injections to prevent low white blood cell counts (neutropenia) in adults with solid tumors getting chemotherapy, radiotherapy, or immunotherapy.
-
First-line treatment with iparomlimab and tuvonralimab plus chemotherapy for esophageal squamous cell carcinoma
This will test whether adding two immunotherapy drugs, iparomlimab and tuvonralimab, to chemotherapy helps people with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma as a first-line treatment.
-
Iparomlimab + Tuvonralimab with apatinib and irinotecan for AFP-producing advanced stomach or gastroesophageal junction cancer
This study will test whether combining two immune drugs (iparomlimab and tuvonralimab) with apatinib and irinotecan helps people with advanced AFP-producing stomach or gastroesophageal junction cancer after progression on first-line PD-1 plus chemotherapy.
-
Adebrelizumab after surgery for esophageal squamous cell cancer.
This Phase 2 trial will test whether giving adebrelizumab after complete surgical removal helps prevent cancer recurrence in adults with esophageal squamous cell carcinoma.
-
Comparing laparoscopic ileocecal reconstruction versus traditional right hemicolectomy for right-sided colon cancer
This trial will see if laparoscopic ileocecal reconstruction right hemicolectomy leads to better cancer-free survival and fewer complications than traditional laparoscopic right hemicolectomy in adults with ascending or proximal transverse colon cancer.
-
Radiotherapy plus QL1706 and Bevacizumab for unresectable liver cancer
This study tests whether adding radiotherapy to immunotherapy plus bevacizumab helps people with unresectable hepatocellular carcinoma see better outcomes.
-
Multi-omics early-warning system to detect organ damage during cancer immunotherapy
This project will try to use multi-omics data and routine clinical measurements from people receiving immune checkpoint inhibitors to build an early-warning system that flags organ damage.
-
Combining radiotherapy and systemic therapy for advanced colon cancer
This study is testing whether combining radiation therapy with chemotherapy and immune treatments can help people with advanced colon cancer have better surgery outcomes and improve their overall health.
-
Local excision and chemoradiotherapy for early-stage rectal cancer
This study is testing whether a combination of surgery and follow-up treatments can help people with early-stage rectal cancer while keeping their bowel function intact.
-
Combining Fruquintinib and Tislelizumab with Radiotherapy for Esophageal Cancer
This study is testing if combining two new cancer treatments, Fruquintinib and Tislelizumab, with radiation can help people with advanced esophageal cancer feel better and improve their outcomes.
-
Neoadjuvant therapy for borderline resectable pancreatic cancer using radiotherapy and immunotherapy
This study is testing a new treatment combining radiation, chemotherapy, and immunotherapy for people with borderline resectable pancreatic cancer to see if it helps them have successful surgery.
-
Breast conserving surgery with intraoperative radiotherapy for early breast cancer
This study is testing whether a new type of radiation given during breast-conserving surgery can help early breast cancer patients have fewer complications and better results compared to the standard radiation treatment.
-
Combining Durvalumab with Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
This study is testing if adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with limited stage small cell lung cancer live longer and feel better.
-
New treatment for metastatic colorectal cancer using liposomal irinotecan
This study is testing a new treatment combining liposomal irinotecan with other medications to see if it helps people with metastatic colorectal cancer who haven't responded to previous therapy.
-
Comparing dalpiciclib with AI to chemotherapy for early breast cancer treatment
This study is testing whether a new treatment combining dalpiciclib with hormone therapy can work as well as standard chemotherapy for postmenopausal women with early breast cancer.
-
Using Tislelizumab and chemotherapy for lung cancer with brain metastases
This study is testing if a new immune therapy combined with chemotherapy can help people with lung cancer that has spread to the brain but isn’t causing symptoms yet.
-
Assessing minimal residual disease in esophageal cancer patients
This study is testing how treatment affects leftover cancer cells in patients with advanced esophageal cancer to see if it helps predict how well the treatment is working.
-
Dalpiciclib for hormone receptor–positive advanced or metastatic breast cancer
This study will test dalpiciclib-containing regimens in adults with hormone receptor–positive advanced or metastatic breast cancer to see if they control the disease and are safe.
-
Chemotherapy with Bevacizumab for HER2-negative Breast Cancer
This study is testing if adding a drug called bevacizumab to chemotherapy can help people with early or locally advanced HER2-negative breast cancer do better before surgery.
-
Using Ensartinib for treating early-stage ALK-positive lung cancer after surgery
This study is testing if the drug Ensartinib can help people with early-stage ALK-positive lung cancer stay cancer-free after surgery.
-
Comparing two nab‑paclitaxel combinations for advanced triple‑negative breast cancer
This test compares nab‑paclitaxel with carboplatin versus nab‑paclitaxel with capecitabine in people with advanced triple‑negative breast cancer who have had up to one prior systemic treatment.
-
Nab-paclitaxel with carboplatin versus nab-paclitaxel with epirubicin before surgery for triple-negative breast cancer
This trial will test whether adding carboplatin or adding epirubicin to nab-paclitaxel before surgery works better for women with triple-negative breast cancer.
-
Combination of nab-paclitaxel and cisplatin before surgery for esophageal cancer
This study is testing if a combination of nab-paclitaxel and cisplatin before surgery can help people with advanced esophageal cancer have better outcomes compared to just having surgery alone.
Quick answers
How many clinical trials run by Hebei Medical University Fourth Hospital are recruiting right now?
29, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 19, Phase 1: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.